Abits
ABTS
Argo Blockchain
ARBK
CATHEDRA BITCOIN INC
CBTTF
Canaan
CAN
The9 Ltd
NCTY
US Stock MarketDetailed Quotes
RGLS Regulus Therapeutics
- 1.5000
- -0.0400-2.60%
Close Dec 30 16:00 ET
- 1.5000
- 0.00000.00%
Post 20:01 ET
98.25MMarket Cap-1.47P/E (TTM)
1.5700High1.4600Low356.75KVolume1.5500Open1.5400Pre Close536.14KTurnover0.73%Turnover RatioLossP/E (Static)65.50MShares3.790052wk High1.13P/B72.99MFloat Cap1.080052wk Low--Dividend TTM48.66MShs Float3071.9974Historical High--Div YieldTTM7.14%Amplitude0.7600Historical Low1.5020Avg Price1Lot Size
About Regulus Therapeutics Company
Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The firm is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in 2007 and is headquartered in San Diego, CA.
Company Profile
SymbolRGLS
Company NameRegulus Therapeutics
Listing DateOct 4, 2012
Issue Price4.00
Founded2007
CEOMr. Joseph P. Hagan
MarketNASDAQ
Employees30
Fiscal Year Ends12-31
Address4224 Campus Point Court,Suite 210
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-202-6300
Websitehttp://www.regulusrx.com
Company Executives
- Name
- Position
- Salary
- Joseph P. Hagan
- Director and Chief Executive Officer
- 2.57M
- Crispina Calsada
- Chief Financial Officer
- 1.07M
- Daniel Penksa
- Vice President, Finance, Controller and Principal Accounting Officer
- --
- Christopher Aker
- Senior Vice President and General Counsel
- 1.09M
- Dr. Stelios Papadopoulos,PhD
- Chairman of the Board
- 131.44K
- Dr. Preston Klassen,M.D.
- Director, President and Head of Research and Development
- --
- Kathryn J. Collier
- Independent Director
- 107.44K
- Pascale Witz, M. Sc.,M.B.A.
- Independent Director
- 93.44K
- Dr. David Baltimore, PhD
- Independent Director
- 95.44K
- Jake R. Nunn
- Independent Director
- 97.44K
- Dr. Hugh Rosen, M.D.,PhD
- Independent Director
- 93.44K
- Dr. William H. Rastetter,PhD
- Independent Director
- 99.44K
- Dr. Alice Shih-hou Huang, PhD
- Independent Director
- 93.44K
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.